Cargando…

5595849 THE GUT MICROBIOME AND HYDROXYUREA EFFECT ON SICKLE CELL DISEASE CHILDREN FROM ANGOLA

Detalles Bibliográficos
Autores principales:	Brito, M., Delgadinho, M., Ginete, C., Santos, B., Vasconcelos, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112500/ http://dx.doi.org/10.1097/01.HS9.0000928132.39710.c7

Ejemplares similares

PI-03: THE EFFECT OF HYDROXYUREA IN THE GUT MICROBIOME OF ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: M., DELGADINHO, et al.
Publicado: (2022)

How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia
por: Delgadinho, Mariana, et al.
Publicado: (2022)

P101: GUT MICROBIOTA IMPACT ON ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: Brito, M, et al.
Publicado: (2022)

5589865 PRELIMINARY FINDINGS FROM THE FOLLOW-UP OF PREGNANT SICKLE CELL DISEASE PATIENTS IN LUANDA, ANGOLA.
por: Brito, M., et al.
Publicado: (2023)

Are Genetic Modifiers the Answer to Different Responses to Hydroxyurea Treatment?—A Pharmacogenetic Study in Sickle Cell Anemia Angolan Children
por: Ginete, Catarina, et al.
Publicado: (2023)

Microbial gut evaluation in an angolan paediatric population with sickle cell disease
por: Delgadinho, Mariana, et al.
Publicado: (2022)

5588995 COMPARATIVE EFFICACY AND SAFETY OF PHARMACOLOGICAL INTERVENTIONS FOR SICKLE CELL DISEASE IN CHILDREN AND ADOLESCENTS: A NETWORK META-ANALYSIS
por: Tonin, F.S., et al.
Publicado: (2023)

Genotypic Diversity among Angolan Children with Sickle Cell Anemia
por: Delgadinho, Mariana, et al.
Publicado: (2021)

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
por: A., POWER-HAYS, et al.
Publicado: (2022)

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

P-057: GENETIC VARIABILITY AND DISEASE SEVERITY IN A COHORT OF ANGOLAN SICKLE CELL DISEASE PATIENTS
por: M., BRITO, et al.
Publicado: (2022)

S105: ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI CONDITIONING IMPROVES DONOR CHIMERISM IN MATCHED SIBLING DONOR STEM CELL TRANSPLANTATION IN ADULT SICKLE CELL DISEASE PATIENTS
por: Dovern, E, et al.
Publicado: (2022)

Efficacy and safety of pharmacological interventions for managing sickle cell disease in children and adolescents: protocol for a systematic review with network meta-analysis
por: Tonin, Fernanda S, et al.
Publicado: (2023)

S125: THE ROLE OF THE MICROBIOME AS A SICKLE CELL DISEASE MODIFIER: AN EXPERT REVIEW
por: Oosterwyk, C, et al.
Publicado: (2022)

P-005: COMPARISON OF SICKLE SCAN AND HEMOTYPE SC AS POINT-OF-CARE NEWBORN SCREENING DIAGNOSTICS FOR SICKLE CELL DISEASE IN LUANDA, ANGOLA
por: B., SANTOS, et al.
Publicado: (2022)

Bacterial Meningitis in Children With Sickle Cell Disease in Angola
por: Pelkonen, Tuula, et al.
Publicado: (2022)

P-048: INFLUENCE OF SEVEN GENETIC POLYMORPHISMS ON THE RESPONSE TO SICKLE CELL DISEASE THERAPY WITH HYDROXYUREA
por: O., FRANCO SANTOS, et al.
Publicado: (2022)

P-034: EFFECTS OF HYDROXYUREA ON SKELETAL MUSCLE MICROVASCULATURE OF MICE WITH SICKLE CELL DISEASE
por: M., RICCETTI, et al.
Publicado: (2022)

5607610 HETEROGENEITY IN COGNITIVE PRESENTATIONS AMONG CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE
por: Hardy, S.J., et al.
Publicado: (2023)

O-12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW-RESOURCE SETTINGS
por: L., SMART, et al.
Publicado: (2022)

P-091: EFFECTS OF CARICA PAPAYA LEAF EXTRACTS IN TRANSCRIPTIONAL REGULATION OF FETAL HEMOGLOBIN
por: M., MENDES, et al.
Publicado: (2022)

P-069: EFFECTS OF QUERCETIN IN TRANSCRIPTIONAL REGULATION OF FETAL HEMOGLOBIN
por: B., CANTEIRO, et al.
Publicado: (2022)

O-08: NEUROCOGNITIVE IMPAIRMENT IN UGANDAN CHILDREN WITH SICKLE CELL ANEMIA COMPARED TO NON-SICKLE SIBLINGS
por: P., BANGIRANA, et al.
Publicado: (2022)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Osunkwo, I, et al.
Publicado: (2022)

5612992 SICKLE CELL HEALTH AWARENESS, PERSPECTIVES, AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND IMPACT ON THE QUALITY OF LIFE OF PATIENTS AND CAREGIVERS IN THE UK
por: Inusa, B.P.D., et al.
Publicado: (2023)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

O-10: SICKLE CELL HEALTH AWARENESS, PERSPECTIVES AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND UNMET NEEDS AS REPORTED BY PATIENTS AND CAREGIVERS
por: I., ODAME, et al.
Publicado: (2022)

S128: CONTINUOUS QUALITY IMPROVEMENT IN PAEDIATRIC SICKLE CELL DISEASE
por: Ahemad, E, et al.
Publicado: (2022)

Mechanistic insights and characterization of cardiomyopathy due to Sickle Cell Disease
por: Patel, Amit R, et al.
Publicado: (2012)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
por: Zahran, Asmaa M., et al.
Publicado: (2020)

5610692 PAIN BURDEN PREDICTS EXECUTIVE FUNCTION IN PAEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Chen, Y., et al.
Publicado: (2023)

5613081 GAPS IN DATA ON GLOBAL PREVALENCE AND BIRTH PREVALENCE OF SICKLE CELL DISEASE AND SICKLE CELL TRAIT: CALL FOR ACTION TO SCALE UP AND HARMONIZE DATA COLLECTION
por: Colombatti, R., et al.
Publicado: (2023)

S127: CONSORTIUM ON NEWBORN SCREENING IN AFRICA FOR SICKLE CELL DISEASE
por: Nnodu, O, et al.
Publicado: (2022)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

O-07: TRANSFUSION PRACTICE, POST-TRANSFUSION COMPLICATIONS AND RISK FACTORS IN SICKLE CELL DISEASE IN SENEGAL
por: M., SECK, et al.
Publicado: (2022)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

A18 INTERKINGDOM DYNAMICS AND NUTRITION ARE ASSOCIATED WITH DIVERGENT MATURATIONAL PATTERNS OF THE INFANT BACTERIAL AND FUNGAL GUT MICROBIOME
por: Mercer, E, et al.
Publicado: (2023)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

O-11: AUTOMATED QUANTIFICATION OF POCKED RED BLOOD CELLS CORRELATES WITH SPLEEN SIZE IN SICKLE CELL DISEASE
por: A., SISSOKO, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v5jtqqairk17mgeklr0665elm5